---
schema_version: "secwatch.filing_event.v1"
accession: "0000934549-22-000041"
form_type: "8-K"
ticker: "ACTG"
cik: "0000934549"
company_name: "ACACIA RESEARCH CORP"
filed_at: "2022-08-11T23:59:59+00:00"
generated_at: "2026-06-24T01:16:19.991344+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Acacia Research Q2 net loss $61.5M; revenue $16.7M; special committee to review Starboard deal

## Summary
- GAAP net loss of $61.5M ($1.44/sh) vs net income of $19.7M ($0.23/sh) in Q2 2021.
- Total revenue $16.7M (IP $8.1M, Industrial $8.7M) down from $17.4M; operating loss $5.7M.
- Repaid $50M of Starboard notes in Q2 and $55M post-quarter; completed $40M share buyback (6.1M shares at avg $4.64).
- Realized gains $11.5M; unrealized losses $57.6M; $26.7M milestone from Mycovia FDA approval expected later in 2022.
- Board formed special committee to review Starboard relationship; pro forma book value $5.87/sh.

## SEC filing metadata
- accession: 0000934549-22-000041
- form_type: 8-K
- ticker: ACTG
- cik: 0000934549
- company_name: ACACIA RESEARCH CORP
- filed_at: 2022-08-11T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/934549/000093454922000041/0000934549-22-000041-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/934549/000093454922000041/actg-20220811.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000934549-22-000041
- JSON: https://secwatch.observer/filing/0000934549-22-000041.json
- Plain text: https://secwatch.observer/filing/0000934549-22-000041.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.